Possible benefits of high-dose chemotherapy as intensive consolidation in patients with high-risk rhabdomyosarcoma who achieve complete remission with conventional chemotherapy

Pediatric Hematology and Oncology

Volumn 20, Issue 3, 2003, Pages 201-210

  Matsubara, Hiroshi ^a,b   Makimoto, Atsushi ^a   Higa, Takeshi ^a   Kawamoto, Hiroshi ^a   Takayama, Jun ^a   Ohira, Mutsuro ^a   Yokoyama, Ryohei ^a   Beppu, Yasuo ^a   Takaue, Yoichi ^a  

^a NATIONAL CANCER CENTER HOSPITAL   (Japan)

^b KYOTO UNIVERSITY HOSPITAL   (Japan)

Author keywords

High dose chemotherapy; Melphalan; Rhabdomyosarcoma; Stemcell transplantation

Indexed keywords

4 HYDROPEROXYCYCLOPHOSPHAMIDE; CARBOPLATIN; CISPLATIN; EPIRUBICIN; ETOPOSIDE; IFOSFAMIDE; MELPHALAN; PIRARUBICIN; THIOTEPA;

ADOLESCENT; ADULT; ARTICLE; AUTOTRANSPLANTATION; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER REGRESSION; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG MEGADOSE; EMBRYONAL CARCINOMA; FEMALE; GASTROINTESTINAL SYMPTOM; HIGH RISK PATIENT; HUMAN; MALE; MUCOSA INFLAMMATION; NAUSEA; NEUTROPENIA; PATHOLOGY; RHABDOMYOSARCOMA; STEM CELL TRANSPLANTATION; STOMACH MUCOSA INJURY; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 0037395270     PISSN: 08880018     EISSN: None     Source Type: Journal    
DOI: 10.1080/08880010390158829     Document Type: Article

References (22)

1. Baker KS, Anderson JR, Link MP, et al. Benefit of intensified therapy for patients with local or regional embryonal rhabdomyosarcoma: results from the Intergroup Rhabdomyosarcoma Study IV. J Clin Oncol. 2000;18:2427-2434.
2. Crist W, Gehan EA, Ragab AH, et al, The Third Intergroup Rhabdomyosarcoma Study. J Clin Oncol. 1995;13:610-630.
3. Klingebiel T, Pertl U, Hess CF, et al. Treatment of children with relapsed soft tissue sarcoma: report of the German CESS/CWS REZ 91 trial. Med Pediatr Oncol. 1998;30:269-275.
4. Atra A, Pinkerton R. Autologous stem cell transplantation in solid tumours of childhood. Ann Med. 1996;28:159-164.
5. Horowitz ME, Kinsella TJ, Wexler LH, et al. Total-body irradiation and autologous bone marrow transplant in the treatment of high-risk Ewing's sarcoma and rhabdomyosarcoma. J Clin Oncol. 1993;11:1911-1918.
6. Koscielniak E, Klingebiel TH, Peters C, et al. Do patients with metastatic and recurrent rhabdomyosarcoma benefit from high-dose therapy with hematopoietic rescue? Report of the German/Austrian Pediatric Bone Marrow Transplantation Group. Bone Marrow Transplant. 1997;19:227-231.
7. Lucidarme N, Valteau-Couanet D, Oberlin O, et al. Phase II study of high-dose thiotepa and hematopoietic stem cell transplantation in children with solid tumors. Bone Marrow Transplant. 1998;22:535-540.
8. Hara J, Osugi Y, Ohta H, et al. Double-conditioning regimens consisting of thiotepa, melphalan and busulfan with stem cell rescue for the treatment of pediatric solid tumors. Bone Marrow Transplant. 1998;22:7-12.
9. Ozkaynak MF, Matthay K, Cairo M, et al. Double-alkylator non-total-body irradiation regimen with autologous hematopoietic stem-cell transplantation in pediatric solid tumors. J Clin Oncol. 1998;16:937-944.
10. Boulad F, Kernan NA, LaQuaglia MP, et al. High-dose induction chemoradiotherapy followed by autologous bone marrow transplantation as consolidation therapy in rhabdomyosarcoma, extraosseous Ewing's sarcoma, and undifferentiated sarcoma. J Clin Oncol. 1998;16:1697-1706.
11. Carli M, Colombatti R, Oberlin O, et al. High-dose melphalan with autologous stem-cell rescue in metastatic rhabdomyosarcoma. J Clin Oncol. 1999;17:2796-2803.
12. Eguchi H, Takaue Y: Peripheral blood stem cell autografts in the treatment of pediatric solid tumors. In: Dicke KA, Keating A, eds. Autologous Marrow and Blood Transplantation. Arlington, VA: The Cancer Treatment Research and Educational Institute; 1995:597-606.
13. Kaplan ES, Meier P. Non-parametric estimation from incomplete observation. J Am Stat Assoc. 1958;53: 457-480.
14. Maurer HM, Beltangady M, Gehan EA, et al. The Intergroup Rhabdomyosarcoma Study, I: a final report. Cancer. 1988;61:209-220.
15. Koscielniak E, Jurgens H, Winkler K, et al. Treatment of soft tissue sarcoma in childhood and adolescence: a report of the German Cooperative Soft Tissue Sarcoma Study. Cancer: 1992;70:2557-2567.
16. Crist WM, Anderson JR, Meza JL, et al. Intergroup Rhabdomyosarcoma Study, IV: results for patients with nonmetastatic disease. J Clin Oncol. 2001;19:3091-3102.
17. Perentesis J, Katsanis E, DeFor T, et al. Autologous stem cell transplantation for high-risk pediatric solid tumors. Bone Marrow Transplant. 1999;24:609-615.
18. Blay JY, Bouhour D, Ray-Coquard I, et al. High-dose chemotherapy with autologous hematopoietic stem-cell transplantation for advanced soft tissue sarcoma in adults. J Clin Oncol. 2000;18:3643-3650.
19. Gadner H. Is there evidence-based benefit of autologous stem cell transplantation in children with solid tumors? Onkologie. 2002;25:278-281.
20. Weigel BJ, Breitfeld PP, Hawkins D, et al. Role of high-dose chemotherapy with hematopoietic stem cell rescue in the treatment of metastatic or recurrent rhabdomyosarcoma. J Pediatr Hematol Oncol. 2001;23:272-276.
21. Pappo A, Anderson JR, Crist WM, et al. Survival after relapse in children and adolescents with rhabdomyosarcoma: a report from the Intergroup Rhabdomyosarcoma Study Group. J Clin Oncol. 1999;17:3487-3493.
22. Grupp SA, Stern JW, Bunin N, et al. Tandem high-dose therapy in rapid sequence for children with high risk neuroblastoma. J Clin Oncol. 2000;18:2567-2575.